Disease Detail

ID DOID:9254
Name mast-cell leukemia
Definition A leukemia that results_in an overwhelming number of tissue mast cells located_in peripheral blood.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia mast-cell leukemia

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
KIT D816V KIT V560G Dasatinib mast-cell leukemia sensitive detail...
KIT D816V KIT V560G Ponatinib mast-cell leukemia sensitive detail...
KIT D816V KIT V560G BPR1J373 mast-cell leukemia sensitive detail...
KIT S476I Midostaurin mast-cell leukemia predicted - sensitive detail...
KIT S476I Nilotinib mast-cell leukemia predicted - sensitive detail...
KIT D816V KIT V560G Avapritinib mast-cell leukemia sensitive detail...
KIT V560G Avapritinib mast-cell leukemia sensitive detail...
Unknown unknown Midostaurin mast-cell leukemia not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02415608 Phase II Ibrutinib Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis Terminated
NCT03580655 Phase II Avapritinib (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis Recruiting